Siglec-5 Activators
Siglec-5 activators are part of a specialized group of biochemical agents designed to interact with a specific class of proteins known as Siglecs, which are sialic acid-binding immunoglobulin-like lectins. Siglec-5 itself is a member of this family characterized by its ability to recognize specific sialic acid residues, a type of sugar molecule that can be found on the surfaces of cells. The structure of Siglec-5 includes an extracellular portion that contains the sialic acid recognition site and typically one or more immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic tail. These ITIMs are critical for its role in cellular signaling processes. Activators of Siglec-5 are molecules that can bind to the sialic acid recognition domain of the protein, thereby influencing its conformation and modulating its interaction with sialic acids. The binding of activators can potentially alter the downstream signaling pathways that are regulated by Siglec-5, which can lead to a variety of cellular responses based on the context of the activation.
The development of Siglec-5 activators involves sophisticated biochemical techniques, aiming to create molecules that precisely engage with the Siglec-5 protein. These activators must have high specificity to ensure that they interact with the intended target without affecting other Siglecs or sialic acid-binding proteins. The design of such activators often requires a deep understanding of the molecular structure of Siglec-5, including the configuration of its sialic acid-binding site and the spatial orientation of key amino acids involved in the recognition process. The specificity is crucial to ensure that the activator's interaction elicits the desired molecular response. Moreover, the creation of Siglec-5 activators encompasses a meticulous process of optimization, where the stability, binding affinity, and selectivity of these molecules are fine-tuned. This process may involve iterative cycles of design, synthesis, and testing to produce activators with the desired properties. The structural diversity of potential activators is vast, as they can range from small organic compounds to complex biologicals, each with its unique mechanism for engaging with Siglec-5.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Calcium ionophore A23187 increases intracellular calcium levels, which is a secondary messenger in many signaling pathways. The rise in calcium can enhance Siglec-5 activation by promoting its conformational change or interaction with calcium-binding partners, possibly leading to the suppression of immune cell activation. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc is an essential trace element that can stabilize the structure of proteins and enhance their function. For Siglec-5, zinc can improve its binding affinity to sialic-acid-containing ligands, thereby enhancing its signaling capacity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus and can lead to the mislocalization of proteins that require proper Golgi processing. Siglec-5, as a membrane protein, may have enhanced activity at the cell surface due to altered trafficking patterns caused by Brefeldin A. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cyclic AMP levels, which can modulate the function of many proteins. Elevated cAMP can enhance the functional activity of Siglec-5 by promoting a cellular environment that supports anti-inflammatory signaling. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). Since GSK-3 can regulate the function of various proteins, inhibition by lithium could enhance Siglec-5 activity by preventing GSK-3 mediated suppression of Siglec-5 associated signaling pathways. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Sodium orthovanadate is a general inhibitor of tyrosine phosphatases. Inhibition of these enzymes can lead to enhanced tyrosine phosphorylation, which might indirectly increase Siglec-5 activity by promoting its association with signaling complexes. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a wide array of proteins. PKC activation can enhance Siglec-5 activity by promoting phosphorylation-dependent signaling events associated with Siglec-5. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 inhibits BET bromodomains, which can lead to altered gene expression profiles. This could indirectly enhance Siglec-5 activity by increasing the expression of genes that are involved in Siglec-5 mediated signaling pathways. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 interacts with its receptors to trigger a signaling cascade that can lead to the activation of adenylate cyclase and increase in cAMP. This can enhance Siglec-5 activity by promoting an anti-inflammatory cellular environment. | ||||||
NAD+, Free Acid | 53-84-9 | sc-208084B sc-208084 sc-208084A sc-208084C sc-208084D sc-208084E sc-208084F | 1 g 5 g 10 g 25 g 100 g 1 kg 5 kg | $57.00 $191.00 $302.00 $450.00 $1800.00 $3570.00 $10710.00 | 4 | |
NAD+ is a cofactor in redox reactions and also serves as a substrate for ADP-ribosylation, which can influence protein function. Elevated levels of NAD+ can enhance Siglec-5 function by impacting signaling pathways where Siglec-5 is involved. | ||||||